A prominent economist doesn’t fear artificial intelligence, but fully embraces it in portfolios. He feels far differently about government debt.
Citi tells investors it’s time to sell Moderna after 600%-plus stock gains
Revenue and profit forecasts fail to justify the hype baked into Moderna’s share price, according to Citi’s analysts.
